Study of DF1001 in Patients with Advanced Solid Tumors

NCT ID: NCT04143711

Last Updated: 2025-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

378 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-11

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having either HER2 activated non-small cell lung cancer, hormone receptor (HR) positive HER2 negative metastatic breast cancer, or HER2 positive metastatic breast cancer. DF1001-001 will be administered as monotherapy or in combination; combinations are DF1001 + nivolumab, DF1001 + Nab paclitaxel, and DF1001 + sacituzumab govitecan-hziy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monotherapy DF1001 Dose Escalation

Dose escalation cohorts of DF1001 in sequential ascending order.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Monotherapy DF1001 Safety/PK/PD Expansion

Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Monotherapy DF1001 Expansion in Urothelial Bladder Cancer

Monotherapy expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 Low)

Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Monotherapy DF1001 Expansion in Cancers with Erbb2 Amplification

Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Combination Therapy with DF1001 and Nivolumab

Combination dose escalation of DF1001 in combination with nivolumab in patients with select solid tumors.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nivolumab

Intervention Type DRUG

Anti-PD-1 immunotherapy agent

Combination Therapy with DF1001 and Nab-paclitaxel

Combination dose escalation of DF1001 in combination with nab-paclitaxel in patients with select solid tumors.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nab paclitaxel

Intervention Type DRUG

A chemotherapy treatment combining paclitaxel with albumin

Combination Therapy with DF1001 and Nivolumab Safety/PK/PD Expansion

Expansion cohort of DF1001 in combination with nivolumab after evaluation for safety in the Combination Therapy with DF1001 and nivolumab Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nivolumab

Intervention Type DRUG

Anti-PD-1 immunotherapy agent

Combination Therapy with DF1001 and Nab-paclitaxel Safety/PK/PD Expansion

Expansion cohort of DF1001 in combination with nab-paclitaxel after evaluation for safety in the Combination Therapy with DF1001 and nab-paclitaxel Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nab paclitaxel

Intervention Type DRUG

A chemotherapy treatment combining paclitaxel with albumin

Combination Therapy with DF1001 and Nivolumab Expansion in Urothelial Bladder Cancer

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nivolumab

Intervention Type DRUG

Anti-PD-1 immunotherapy agent

Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 High)

Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Monotherapy DF1001 Expansion in NSCLC

Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Combination Therapy with DF1001 and Nivolumab Expansion in NSCLC

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nivolumab

Intervention Type DRUG

Anti-PD-1 immunotherapy agent

Monotherapy DF1001 Expansion in Gastric Cancer

Monotherapy expansion cohort enrolling up to 20 patients with gastric cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Combination Therapy with DF1001 and Nivolumab Expansion in Gastric Cancer

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with gastric cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nivolumab

Intervention Type DRUG

Anti-PD-1 immunotherapy agent

Monotherapy DF1001 Expansion in Esophageal Cancer

Monotherapy expansion cohort enrolling up to 20 patients with esophageal cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Combination Therapy with DF1001 and Nivolumab Expansion in Esophageal Cancer

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with esophageal cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Nivolumab

Intervention Type DRUG

Anti-PD-1 immunotherapy agent

Monotherapy DF1001 Exploratory Efficacy Expansion in NSCLC

Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documentation of HER2 activation.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Combo Therapy with DF1001 and Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in NSCLC

Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 20 patients, including safety lead-in, with non-small cell lung cancer with documentation of HER2 activation.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Sacituzumab Govitecan-hziy

Intervention Type DRUG

A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

Monotherapy DF1001 Exploratory Efficacy Expansion in Metastatic Breast Cancer (HR+/HER2-)

Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documentation of HR positive and HER2 negative expression.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HER2+)

Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HER2 positive expression.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Sacituzumab Govitecan-hziy

Intervention Type DRUG

A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HR+/HER2-)

Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HR positive and HER2 negative expression.

Group Type EXPERIMENTAL

DF1001

Intervention Type DRUG

Immunotherapy agent targeting NK cells.

Sacituzumab Govitecan-hziy

Intervention Type DRUG

A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DF1001

Immunotherapy agent targeting NK cells.

Intervention Type DRUG

Nivolumab

Anti-PD-1 immunotherapy agent

Intervention Type DRUG

Nab paclitaxel

A chemotherapy treatment combining paclitaxel with albumin

Intervention Type DRUG

Sacituzumab Govitecan-hziy

A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed written informed consent.
2. Male or female patients aged ≥ 18 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months.
4. Baseline Left Ventricular Ejection Fraction (LVEF) ≥ 55% measured by echocardiography (preferred) or multigated acquisition (MUGA) scan.
5. Adequate hematological function.
6. Adequate hepatic function.
7. Adequate renal function.
8. Effective contraception for women of child bearing potential (WOCBP) patients as defined by World Health Organization (WHO) guidelines for 1 "highly effective" method or 2 "effective" methods.


1. Have progression of unresectable locally advanced or metastatic NSCLC after last systemic therapy (as confirmed by investigator) or be intolerant of last systemic therapy.
2. Have HER2 overexpression status (IHC 2+ or 3+), or ERBB2 amplification, or HER2 activating mutation
3. Have recurrent or progressive disease during or after platinum doublet-based chemotherapy.
4. Have received and progressed on or after anti-PD-(L)1 therapy.


1. Documented evidence of HR+ metastatic breast cancer
2. Documented evidence of HER2- status.
3. Disease progression or recurrence after prior therapy.


1. Have histologically confirmed HER2+ breast cancer.
2. Have received prior treatment with trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), or trastuzumab deruxtecan (T-DXd).
3. Have progression of unresectable locally advanced metastatic breast cancer after last systemic therapy or be intolerant of last systemic therapy.


1. Evidence of objective disease, but participation does not require a measurable lesion.
2. Locally advanced or metastatic solid tumors, for which no standard therapy exists, or standard therapy has failed.
3. HER2 expression by immunohistochemistry and/or erbb2 amplification and/or erbb2 activating mutations.


1. Eligible to receive nivolumab per its label for a malignancy of epithelial origin; or
2. Have no standard therapy available, or standard therapy has failed, and must not have received nivolumab prior to joining the study.
3. HER2 expression by immunohistochemistry and/or ebb2 amplification and/or erbb2 activating mutations must be documented on either archival tissue or fresh tumor biopsy.


1. Patients must be eligible for treatment with nab-paclitaxel per its label, or have no standard therapy available, or standard therapy has failed.
2. HER2 expression by immunohistochemistry and/or erbb2 amplification and/or erbb2 activating mutations must be documented on either archival tissue or fresh tumor biopsy.


1. Fresh tumor biopsy must be obtained during the screening window.
2. HER2 expression by immunohistochemistry (IHC).
3. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary urothelial, urethra).
3. Patients must have received a platinum containing chemotherapy and an anti PD-1 or anti PD-L1 for the treatment of urothelial bladder cancer.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1
2. Histologically documented (metastatic or locally advanced) breast cancer.
3. Absence of erbb2 amplification by ISH and/or HER2 IHC of 0, 1+, or 2+.
4. Patient must have progressed after one line of systemic chemotherapy.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1
2. Histologically documented (metastatic or locally advanced) breast cancer.
3. Erbb2 amplification by ISH and/or HER2 IHC of 3+, or 2+. If Herceptest score is 2+, ISH results should demonstrate erbb2 amplification.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Documented history of erbb2 amplification.
3. Patients must have received at least one line of an approved or established therapy.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Advanced (unresectable/recurrent/metastatic) gastric cancer or cancer of the gastro-esophageal junction.
3. Tumor must have been declared HER2 positive.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Advanced (unresectable/recurrent/metastatic) gastric cancer or cancer of the gastro-esophageal junction.
3. Tumor must have been declared HER2 low; ISH non-amplified and/or HER2 IHC of 0, 1+ or 2+. If Herceptest score is 0, HER2 must be detected by IHC on at least 1+ of the tumor cells.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Advanced (unresectable/recurrent/metastatic) esophageal cancer.
3. Tumor must have been declared HER2 positive.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Advanced (unresectable/recurrent/metastatic) esophageal cancer.
3. Tumor must have been declared HER2 low; ISH non-amplified and/or HER2 IHC of 0, 1+ or 2+. If Herceptest score is 0, HER2 must be detected by IHC on at least 1+ of the tumor cells.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Histologically confirmed NSCLC meeting stage criteria for stage IIIB, stage IV, or recurrent disease that has been confirmed to have HER2 expression (at least 1+, however, patients must not carry an erbb2 amplification) via archival or fresh biopsy tissue prior to study enrollment.
3. Patients must have recurrent or progressive disease during or after platinum doublet-based chemotherapy.


1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
2. Histologically confirmed NSCLC meeting stage criteria for stage IIIB, stage IV, or recurrent disease that has been confirmed to have amplification of erbb2 via archival or fresh biopsy tissue prior to study enrollment.
3. Patients must have recurrent or progressive disease during or after platinum doublet-based chemotherapy.

Exclusion Criteria

1. Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy \[with the exception of palliative bone directed radiotherapy\], immune therapy, or cytokine therapy except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days or 5 half-lives before the start of study treatment. Note: Patients receiving bisphosphonates are eligible provided treatment was initiated at least 14 days before the first dose of DF1001.
2. Previous malignant disease other than the target malignancy to be investigated in this study within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ.
3. Rapidly progressive disease.
4. Active or history of central nervous system (CNS) metastases.
5. Receipt of any organ transplantation including autologous or allogeneic stem-cell transplantation.
6. Significant acute or chronic infections (including historic positive test for human immunodeficiency virus \[HIV\], or active or latent hepatitis B or active hepatitis C tested during the screening window).
7. Preexisting autoimmune disease (except for patients with vitiligo) needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years or clinically relevant immunodeficiencies (eg, dys-gammaglobulinemia or congenital immunodeficiencies), or fever within 7 days of Day 1.
8. Known severe hypersensitivity reactions to mAbs (≥ Grade 3 NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly controlled asthma).
9. Persisting toxicity related to prior therapy \> Grade 1 NCI-CTCAE v5.0, however alopecia and sensory neuropathy ≤ Grade 2 is acceptable.
10. Pregnancy or lactation in females during the study.
11. Known alcohol or drug abuse.
12. Serious cardiac illness
13. NYHA III of IV heart failure or systolic dysfunction (LVEF \< 55%)
14. High-risk uncontrolled arrhythmias ie, tachycardia with a heart rate \> 100/min at rest
15. Significant ventricular arrhythmia (ventricular tachycardia) or higher-grade Atrioventricular block (AV-block; second-degree AV-block Type 2 \[Mobitz 2\] or third-degree AV-block)
16. Angina pectoris requiring anti-anginal medication
17. Clinically significant valvular heart disease
18. Evidence of transmural infarction on ECG
19. Poorly controlled hypertension (defined by: systolic \> 180 mm Hg or diastolic \> 100 mm Hg)
20. Clinically relevant uncontrolled cardiac risk factors, clinically relevant pulmonary disease or any clinically relevant medical condition in the opinion of the Investigator that may limit participation in this study.
21. Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.
22. All other significant diseases (e.g., inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient's ability to participate
23. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
24. Legal incapacity or limited legal capacity.
25. Incapable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol .
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dragonfly Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California Irvine Medical Center

Irvine, California, United States

Site Status RECRUITING

University of Southern California

Los Angeles, California, United States

Site Status RECRUITING

Sharp Healthcare

San Diego, California, United States

Site Status RECRUITING

University of California San Francisco

San Francisco, California, United States

Site Status RECRUITING

University of Kansas Medical Center Research Institute, Inc.

Westwood, Kansas, United States

Site Status ACTIVE_NOT_RECRUITING

Louisiana State University

New Orleans, Louisiana, United States

Site Status RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, United States

Site Status RECRUITING

University of Michigan

Ann Arbor, Michigan, United States

Site Status WITHDRAWN

Henry Ford Health System

Detroit, Michigan, United States

Site Status WITHDRAWN

Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center

New York, New York, United States

Site Status ACTIVE_NOT_RECRUITING

Montefiore Einstein Center for Cancer Care

The Bronx, New York, United States

Site Status RECRUITING

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Site Status RECRUITING

The Ohio State University

Columbus, Ohio, United States

Site Status RECRUITING

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, United States

Site Status WITHDRAWN

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status RECRUITING

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Site Status RECRUITING

MD Anderson Cancer Center

Houston, Texas, United States

Site Status RECRUITING

Multicare Health System Tacoma General Hospital

Tacoma, Washington, United States

Site Status ACTIVE_NOT_RECRUITING

University of Wisconsin

Madison, Wisconsin, United States

Site Status RECRUITING

Centre Hospitalier de l'Ardenne

Arlon, , Belgium

Site Status RECRUITING

Grand Hopital de Charleroi

Charleroi, , Belgium

Site Status RECRUITING

Domaine Universitaire du Sart Tilman; CHU de Liege

Liège, , Belgium

Site Status RECRUITING

Rigshospitalet

Copenhagen, Capital Region, Denmark

Site Status RECRUITING

Herlev og Gentofte Hospital

Herlev, , Denmark

Site Status RECRUITING

Institut Curie

Paris, Paris, France

Site Status RECRUITING

Groupe Hospitalier Saint Andre

Bordeaux, , France

Site Status RECRUITING

Centre Georges-Francois Leclerc

Dijon, , France

Site Status RECRUITING

Centre Oscar Lambret

Lille, , France

Site Status RECRUITING

Centre Leon Berard

Lyon, , France

Site Status RECRUITING

Institut Paoli Calmettes

Marseille, , France

Site Status RECRUITING

Institut Regional du Cancer de Montepelier

Montpellier, , France

Site Status RECRUITING

Groupe Hospitalier Pitie Salpetriere

Paris, , France

Site Status RECRUITING

CHU de Rennes Hopital Pontechaillou

Rennes, , France

Site Status RECRUITING

ICO - Site Rene Gauducheau

Saint-Herblain, , France

Site Status RECRUITING

Institut Claudius Regaud

Toulouse, , France

Site Status RECRUITING

Amsterdam University Medical Center

Amsterdam, , Netherlands

Site Status ACTIVE_NOT_RECRUITING

Universitair Medisch Centrum Groningen

Groningen, , Netherlands

Site Status ACTIVE_NOT_RECRUITING

Maasticht University Medical Center

Maastricht, , Netherlands

Site Status ACTIVE_NOT_RECRUITING

Radboud University Nijmegen

Nijmegen, , Netherlands

Site Status ACTIVE_NOT_RECRUITING

Erasmus University Medical Center

Rotterdam, , Netherlands

Site Status ACTIVE_NOT_RECRUITING

UMC Utrecht

Utrecht, , Netherlands

Site Status ACTIVE_NOT_RECRUITING

Inje University Haeundae Paik Hospital

Busan, , South Korea

Site Status RECRUITING

Kosin University Gospel Hospital

Busan, , South Korea

Site Status RECRUITING

National Cancer Center

Goyang-si, , South Korea

Site Status RECRUITING

Ajou University Hospital

Gyeonggi-do, , South Korea

Site Status RECRUITING

CHA Bundang Medical Center, CHA University

Gyeonggi-do, , South Korea

Site Status RECRUITING

Seoul National University Bundang Hospital

Seongnam, , South Korea

Site Status RECRUITING

Asan Medical Center

Seoul, , South Korea

Site Status RECRUITING

Korea University Guro Hospital

Seoul, , South Korea

Site Status RECRUITING

Seoul National University Hospital

Seoul, , South Korea

Site Status RECRUITING

Severance Hospital

Seoul, , South Korea

Site Status RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Denmark France Netherlands South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Clinical Trials

Role: CONTACT

617-588-0086

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jennifer Valerin, M.D.

Role: primary

Anthony El-Khoueiry, M.D.

Role: primary

Charles Redfern, M.D.

Role: primary

Pamela Munster, MD

Role: primary

Agustin Garcia, M.D.

Role: primary

Vincent Lam, M.D.

Role: primary

Eric Feldman, M.D.

Role: primary

Alberto J Montero, M.D., MBA

Role: primary

Robert Wesolowski, M.D.

Role: primary

Howard Safran, M.D.

Role: primary

Jordan Berlin, M.D.

Role: primary

Ecaterina Dumbrava, M.D.

Role: primary

Nataliya Uboha, M.D.

Role: primary

Frederic Forget, M.D.

Role: primary

David Schroder, M.D.

Role: primary

Christine Gennigens, M.D.

Role: primary

Kristoffer Rohrberg, M.D.

Role: primary

Rikke Eefsen, M.D.

Role: primary

Emanuela Romano, M.D.

Role: primary

Alain Ravaud, M.D.

Role: primary

Francois Ghiringhelli, MD

Role: primary

Nicolas Penel, M.D.

Role: primary

Phillippe Cassier, M.D.

Role: primary

Cecile Vicier, M.D.

Role: primary

Diego Tosi, MD

Role: primary

Aurore Vozy, MD

Role: primary

Lena Herve, MD

Role: primary

Mario Campone, M.D.

Role: primary

Carlos-Alberto Gomez-Roca, M.D.

Role: primary

Il-hwan Kim, MD

Role: primary

Seong-Hoon Shin, MD

Role: primary

Keun Seok Lee, MD

Role: primary

Tae Hwan Kim, MD

Role: primary

Yong Wha Moon, MD

Role: primary

Jee Hyun Kim, MD

Role: primary

Sung Bae Kim, MD

Role: primary

In Hae Park, MD

Role: primary

Kyung-Hung Lee, MD

Role: primary

Min Hwan Kim, MD

Role: primary

Sook Hee Hong, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DF1001-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Trial of DFP-14927 in Advanced Solid Tumors
NCT03943004 RECRUITING PHASE1
Study of AS1411 in Advanced Solid Tumours
NCT00881244 COMPLETED PHASE1
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279 ACTIVE_NOT_RECRUITING PHASE1/PHASE2